VESALIUS-CV: Evolocumab cuts first MACE 31% in high-risk primary prevention
Amgen PRs/Marston: Repatha + statin 31% RRR/1.8-2.8% ARR high-risk no ASCVD (LDL→45 mg/dL, stroke cut); bolsters PCSK9 primary per 2026 guideline.
Sources (2)
Updated Apr 9, 2026